Showing 501 - 520 results of 13,723 for search '(( a ((teer decrease) OR (linear decrease)) ) OR ( a ((largest decrease) OR (greatest decrease)) ))', query time: 0.63s Refine Results
  1. 501
  2. 502
  3. 503
  4. 504

    Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia by Cassandra N. Spracklen (3131484)

    Published 2016
    “…<i>Results</i>: The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82–0.96). …”
  5. 505

    S1 Dataset - by Tomohiro Gonjo (8825780)

    Published 2023
    “…Nine swimmers maintained one coordination pattern, but other swimmers switched their coordination during the trial, particularly by shortening the duration of the glide with arms at the side. LMM showed a linear decrease (from the first to the last turn) in the time gap between the end of the dolphin kick and the start of the arm pull-out (a glide with the streamlined body position; F = 9.64, p = 0.034) and the glide duration with the arms at the side (F = 11.66, p = 0.015). …”
  6. 506
  7. 507
  8. 508
  9. 509

    Selected metabolic traits significantly associated with FFMI<sup>a</sup> in a linear regression model adjusted for age and sex in the KORA S4 sample. by Carolin Jourdan (155791)

    Published 2012
    “…a<p>Fat Free Mass Index;</p>b<p>direction of the association (positive or negative);</p>c<p>for multiple testing adjusted p-value;</p>d<p>adjusted R<sup>2</sup> of the linear model;</p>e<p>p-gain, fold decrease in the p-value of association for the pair of metabolites, compared to the lowest of two p-values for the single metabolites;</p>f<p>confirmed in KORA F4, for * significance and direction; # confirmed for xLeu in F4, n.a., metabolite was not available in F4; AAs, amino acids; Σ aromatic amino acids, sum of tyrosine, phenylalanine, and tryptophan; Σ BCAAs, sum of valine, isoleucine, and leucine; Σ glucogenic amino acids, sum of alanine, glycine, and serine.…”
  10. 510

    BMT decreased weight of different organs. by Saeed Katiraei (3956147)

    Published 2017
    “…<p>(A) BMT decreased the weight of liver, thymus, spleen and the pancreas both on LFD and HFD. …”
  11. 511
  12. 512

    Decreased immunofluorescence during multiplex staining. by Sandrine Prost (38667)

    Published 2016
    “…The intensity of fluorescence is affected by the number of staining rounds (p<0.001, ANOVA) and the Qdot type (p<0.001, ANOVA): intensity decreases with the incremental number of subsequent staining rounds, and the reduction is greater for Vivid than original Qdots, (fitted linear regression slopes for absolute and (in brackets) relative brightness change with each additional staining round: -0.02 (-0.11) for Qdot 565; -0.22 (-0.23) for Qdot 605Vivid; -0.14 (-0.17) for Qdot 705Vivid). …”
  13. 513

    Linear trajectories of IL-6. by Lucio Manenti (4503532)

    Published 2021
    “…Data values are indicated by circles the diameter of which is proportional to the inverse probability of treatment weight based on propensity score which was used in the analysis for comparison between treatment groups. The linear decreasing trend was statistically significant (P<0.001).…”
  14. 514
  15. 515
  16. 516

    List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon. by Karsten Suhre (67967)

    Published 2010
    “…<p>List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon.…”
  17. 517
  18. 518
  19. 519
  20. 520